Research Links Diabetes and Weight Loss Medications to Rare Eye Disorder That Can Cause Blindness

Recent research has uncovered a concerning link between two popular medications for diabetes and weight loss—Ozempic and Wegovy—and a rare eye condition that can lead to blindness.

According to media reports, a new study has found that individuals taking these medications may face an increased risk of developing NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy), a rare eye disorder that can result in sudden vision loss.

NAION is a condition where the optic nerve, which contains over a million tiny fibers, does not receive enough blood flow, leading to a sudden loss of vision. It affects only a small number of individuals, and unfortunately, no effective treatment has yet been found.

The research revealed that people taking semaglutide (the active ingredient in both Ozempic and Wegovy) for diabetes are four times more likely to develop NAION. For those using it for weight loss, the risk is seven times higher.

**Eye Specialist’s Warning**

According to eye expert Dr. Rizo, “I am not saying that patients should stop taking their medication, but this is a warning to be more cautious.” He emphasized that doctors and patients should carefully discuss the risks and benefits of using these drugs before deciding to continue treatment.

The study further highlighted that the risk of NAION is seven times higher for people using semaglutide for obesity treatment compared to a fourfold increase for those using it for type 2 diabetes.

**Findings from the Study**

The study examined 710 patients with type 2 diabetes and found that among those taking semaglutide, about 9% developed NAION, compared to less than 2% of those using other medications. This raised serious concerns about the potential risks of these popular drugs, particularly in individuals using them for weight loss.

**Conclusion**

While Ozempic and Wegovy are widely prescribed for managing diabetes and aiding weight loss, the new research underscores the importance of closely monitoring patients for potential side effects, including the rare and serious risk of NAION. Health professionals and patients must weigh the benefits against these risks before making decisions about treatment.